openPR Logo
Press release

New Detailed Review of Oral Ketamine for Depression Published in JCP

04-17-2019 09:54 AM CET | Health & Medicine

Press release from: Physicians Postgraduate Press

Memphis, TN (April 16, 2019) – A review article published today in The Journal of Clinical Psychiatry indicates that orally administered ketamine is efficacious for depression but may take longer to yield results. The review, authored by Joshua D. Rosenblat and colleagues at the University of Toronto, analyzed 13 articles, including 2 randomized controlled trials (RCTs).

The RCTs demonstrated antidepressant efficacy and good tolerability for oral ketamine, but significant changes in depressive symptom severity were observed only after 2–6 weeks of treatment. This lag time is in contrast to the rapid effects of intravenous ketamine, which has been investigated for its antidepressant and antisuicidal effects over the past 2 decades.

Ketamine is an anesthetic agent that works differently from currently available antidepressants. Intranasal esketamine, approved by the FDA in March for treatment-resistant depression, and oral ketamine represent alternatives to intravenous ketamine, which can present challenges in terms of accessibility.

Due to risks of sedation and dissociative effects, as well as possible misuse, the FDA approval of intranasal esketamine requires that the drug be administered in a medical office where the patient can be monitored for 2 hours afterward. Rosenblat and colleagues note that, intriguingly, dissociative effects, often reported with IV ketamine, were rarely observed in the studies of oral ketamine. However, they caution that oral ketamine might lend itself to take-home doses that could be diverted or misused without adequate precautions. Given these concerns, along with insufficient current evidence, they emphasize that prescribing oral ketamine for depression cannot be recommended until further evidence is available.

Access the entire article, “Oral Ketamine for Depression: A Systematic Review,” by Joshua D. Rosenblat, MD; Andre F. Carvalho, MD, PhD; Madeline Li, MD, PhD; Yena Lee, BSc; Mehala Subramanieapillai, MSc; and Roger S. McIntyre, MD, at

The Journal of Clinical Psychiatry, a peer-reviewed publication that is indexed and abstracted by the National Library of Medicine’s PubMed, is the official publication of the American Society of Clinical Psychopharmacology and is among the top 10 most cited psychiatry journals worldwide.

Physicians Postgraduate Press, Inc.
Post Office Box 752870
Memphis, Tennessee 38175-2870

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Detailed Review of Oral Ketamine for Depression Published in JCP here

News-ID: 1705762 • Views:

More Releases from Physicians Postgraduate Press

Antioxidants May Aid in the Treatment of Tardive Dyskinesia
Memphis, TN (May 9, 2019) – Today, The Primary Care Companion for CNS Disorders published a case report on the use of antioxidants in the treatment of tardive dyskinesia. While new pharmacologic discoveries have occurred in the area of movement disorders, their use comes with a large price tag. Thus, for mild cases, clinicians may want to seek out more cost-effective options. Antioxidants may serve a role in the prevention
Immigrants at Lower Risk of Substance Use, Psychiatric Disorders Than US-Born Counterparts
Immigrants at Lower Risk of Substance Use, Psychiatric Disorders Than US-Born Co …
Memphis, TN (February 28, 2019) – Today The Primary Care Companion for CNS Disorders published a study comparing prevalence rates of alcohol, nicotine, and other drug use and major psychiatric disorders between US-born and foreign-born Mexican Americans and non-Hispanic whites. Hispanics are the leading ethnic majority in the US, and Mexican Americans constitute 60% of the US Hispanic population. Therefore, focus on this group is timely and important, especially since

More Releases for Clinical

Clinical Laboratory Market in Indonesia, Clinical Laboratory Industry in Indones …
"Increase in healthcare expenditure from the Indonesian government has driven the growth of clinical laboratory market in Indonesia." Increase in Healthcare Awareness: Largely driven by increase in healthcare spending by aging population (~$ 260 per person by 2050), rising income levels, rising awareness for preventive testing, advanced healthcare diagnostic tests offerings, and central government's healthcare measures. Developments in Testing and Preference for Evidence based testing: There is also a rising number
Clinical solutions
Are you spending more time with yellow files than with patients? Healthbridge can change that with our intuitive and easy to use clinical platform that is designed specifically for the medical practitioner at the practice. smaller2 Easily access patient information Cloud-based technology enables you to store rich clinical information that can be easily accessed as and when you need it. Medical billing software innovation Become a paperless practice Create scripts, sick notes, and clinical notes electronically. Plus, have
Clinical Research and Clinical Trials Summit
Clinical Research 2019 has been designed in an interdisciplinary manner with a multitude of tracks to choose from every segment and provides you with a unique opportunity to meet up with peers from both industry and academia and establish a scientific network between them. We cordially invite all concerned people to come join us at our event and make it successful by your participation. This is the premier interdisciplinary forum for
Paediatric Clinical Trial Conference - When designing a Paediatric clinical tria …
Press Release – 12.02.2018 When designing a Paediatric clinical trial, a paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, to support the authorisation of a medicine for children. All applications for marketing authorisation for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral
Clinical Communication
According to a recent market report published by Persistence Market Research titled “Clinical Communication and Collaboration Market: Global Industry Analysis (2012–2016) and Forecast (2017–2025),” revenue from the global clinical communication and collaboration market was US$ 138.5 Mn in 2012 and US$ 214.8 Mn in 2016, representing a CAGR of 11.6% from 2012 to 2016. This revenue growth is attributed to addition of new features in clinical communication and collaboration solutions.
E-Clinical Trial Solutions Market To Accelerating Clinical Development Technolog …
The study of the "Global e-Clinical Trial Solutions Market" provides the market size information and market trends along with the factors and parameters impacting it in both short and long term. The study ensures a 360° view, bringing out the complete key insights of the industry. The Global e-Clinical Trial Solutions Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the e-Clinical